Atopic Dermatitis

What is the relationship between mental disorders and atopic dermatitis? Investigators from a recent study endeavored to find out.

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

A review of topical JAK inhibitor ruxolitinib.

The American Academy of Dermatology’s newest guideline focuses on awareness of other health conditions associated with atopic dermatitis in adult patients.

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.

Click to answer this week's poll on the newly released AAD guidelines on AD comorbidites.

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.

A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.

A long-term study of 2 British cohorts with atopic dermatitis (AD) reveals 4 distinct disease patterns occurring between birth and midlife.

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

Patients suffering from a wide range of dermatologic diseases can benefit from the new and exciting therapies and treatment modalities that have recently become available.

Neal Bhatia, MD, highlights the most exciting new drugs and therapies in atopic dermatitis and psoriasis in his presentation at the current Maui Derm for Dermatologists meeting.

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Click here to answer this week's poll.

The FDA has approved abrocitinib for adult patients with moderate to severe AD.

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

AbbVie announces the approval after 3 studies show the efficacy and safety of upadacitinib using mono- and combination therapy.

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference.

Treatments awaiting FDA approval could bolster the range of nonsteroids and well-tolerated topicals aimed at combating pediatric cutaneous disorders.

In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.

In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).

Skin sensitivity will be a factor in vehicles for new treatments.

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.